Study Investigating a New Immunotherapy (INBRX-105) for Patients with Advanced Head and Neck Cancer (PDL1x41BB)

What does this study investigate?

This is a Phase 1/Phase 2, open label study, of the drug INBRX-105, for PD-L1 positive, advanced Head and Neck Cancer patients.

Presently more than 137 patients have already been treated with INBRX-105. The study is currently enrolling in Phase 2 ('expansion'), meaning that a larger group of patients will be treated with the study drug, at a predetermined dose that was demonstrated to be well-tolerated in Phase 1 portion of the study.

The study is enrolling patients with tumors that cannot be surgically removed, or that have spread to other organs (metastatic), and did not respond to standard treatments such as checkpoint inhibitors (CPI).

'Open-label' means that both you and your study doctor will know what study drug you will be receiving during the trial.

PD-L1 positivity means that the protein PD-L1 is found on your cancer cells. The reason for this is that PD-L1 is a special "marker" that may affect your response to the study drug.

All participants will be given an investigational medication, INBRX-105.

What is the study medication?

INBRX-105 is an investigational immunotherapy medication that focuses on harnessing the power of your own immune system to combat cancer.

INBRX-105 functions similarly to antibodies and comprises specific binding domains for PD-L1 and 4-1BB proteins. Rather than being composed of PD-L1 and 4-1BB themselves, INBRX-105 selectively binds to the PD-L1 present on cancer cells and activates T lymphocytes of the immune system through their 4-1BB protein. This process augments your immune system in recognizing and selectively attacking cancer cells, while sparing normal cells.

Additionally, INBRX-105 has the potential to synergize with FDA approved PD-1 blocking antibodies, like pembrolizumab (KEYTRUDA®).

What are the main objectives of the study?

1. Further confirm the recommended dose of INBRX-105 in a larger group of patients
2. Continue to evaluate the safety of INBRX-105 and evaluate how well your body tolerates the study treatment
3. Determine if INBRX-105 decreases the size of your tumor(s) or prevents growth of your tumor(s)

Study treatments and schedule

If you are determined to be a suitable study candidate and consent to participating in this study, you will engage in three key phases of this study:

1. **Screening**: Up to 28 days to confirm study eligibility.
2. **Treatment**: You will receive INBRX-105 alone or in combination with standard of care pembrolizumab (KEYTRUDA®) by intravenous (IV) infusion.
3. **Follow up:** After you finish study treatment, your study doctor will continue to follow-up with you at least once every 3 months, for at least 12 months or until

you decide that you no longer want to participate and withdraw consent and remove yourself from the study.

Will I be reimbursed for my participation?

An allowance to off-set the cost of travel and accommodations may be available. You will be able to get more information about the reimbursement process when you inquire about this study with us and/or with the study site.

Who is sponsoring this study?

This study is sponsored by Inhibrx, Inc., a clinical-stage biopharmaceutical company dedicated to helping people with life-threatening conditions through scientific innovation and excellence.

Next Steps

1. Email our clinical team at clinicalteam@trialjectory.com or schedule time with a specialist at https://calendly.com/support-cancer-patients to see if this trial might be for you, and receive answers to any questions you may have
2. You can download this information as a PDF and give it to your oncologist or other members of your support team.
3. Additional information about the trial can be found at https://clinicaltrials.gov/ct2/show/NCT03809624
4. We will work with you to apply directly to your desired study location and provide any assistance you may need along the way.